Abstract: The present disclosure provides methods of preparing pharmaceutical compositions containing cocrystals through the combination application of dielectric heating and distributive and dispersive mixing such as hot melt extrusion (HME). The cocrystals used in these compositions may be formed using an active pharmaceutical ingredient and a co-former. The co-former may be either an excipient or a second active pharmaceutical ingredient. These pharmaceutical compositions may be used in the treatment of a disease or disorder.

Abstract: The present disclosure provides methods of preparing pharmaceutical compositions using an additive manufacturing technique containing cocrystals. The cocrystals used in these compositions may be formed using an active pharmaceutical ingredient and a co-former. The co-former may be either an excipient or a second active pharmaceutical ingredient. These pharmaceutical compositions may be used in the treatment of a disease or disorder.

Abstract: The present disclosure provides cocrystals of an active pharmaceutical ingredient and a co-former. The co-former may be either an excipient or a second active pharmaceutical ingredient. These particular co-crystals may be made through either an extension based process or a solvent based method. These cocrystals may be used in additive manufacturing processes. These pharmaceutical compositions may be used in the treatment of a disease or disorder.

Abstract: The present disclosure provides pharmaceutical compositions prepared using an additive manufacturing process where the active pharmaceutical ingredient has been rendered into the amorphous form or prepared as an amorphous solid dispersion at a temperature below the melting point of the active pharmaceutical ingredient or the glass transition of the physical mixture or composition of the individual components. The present disclosure also provides methods of preparing these compositions by using properties such as the chamber and surface temperature and the electron laser density.

Abstract: The present disclosure provides pharmaceutical compositions which exhibit improved flowability as measured by the angle of repose. The pharmaceutical compositions comprise an active pharmaceutical ingredient, two or more absorbents, and optionally surfactant. These pharmaceutical compositions may be used in the manufacturing of pharmaceutical dosage forms or an additive manufacturing process such as 3D selective laser sintering printing.

Abstract: A method of producing an extruded, powdered/granulated composition comprising an active pharmaceutical ingredient (API), by the steps of providing an API and a porous inorganic excipient, and processing them by an extrusion process to directly produce an extruded, powdered/granulated composition wherein the API is at least partially absorbed within the pores of the inorganic excipient. In preferred embodiments, the API is melted, or solubilised in a solubilizer.

Abstract: The invention relates to a process of preparing a salt of an active pharmaceutical ingredient, the process comprising providing a blend of an active pharmaceutical ingredient and a salt forming substance, mixing the blend, optionally in the presence of added water, to react the active pharmaceutical ingredient with the salt forming substance to provide the salt of the active pharmaceutical ingredient; wherein when the active pharmaceutical ingredient is acidic, the salt forming substance is a base and the pKa difference between the acidic active pharmaceutical ingredient and the base is greater than 1, typically greater than 2 or preferably greater than 3; or when the active pharmaceutical ingredient is basic, the salt forming substance is an acid and the pKa difference between the basic active pharmaceutical ingredient and the acid is greater than 1, typically greater than 2 or preferably greater than 3.

Abstract: The invention relates to a process of preparing a salt of an active pharmaceutical ingredient, the process comprising providing a blend of an active pharmaceutical ingredient and a salt forming substance, mixing the blend, optionally in the presence of added water, to react the active pharmaceutical ingredient with the salt forming substance to provide the salt of the active pharmaceutical ingredient; wherein when the active pharmaceutical ingredient is acidic, the salt forming substance is a base and the pKa difference between the acidic active pharmaceutical ingredient and the base is greater than 1, typically greater than 2 or preferably greater than 3; or when the active pharmaceutical ingredient is basic, the salt forming substance is an acid and the pKa difference between the basic active pharmaceutical ingredient and the acid is greater than 1, typically greater than 2 or preferably greater than 3,

Abstract: The present invention relates to a method of producing a direct compression tablet composition comprising the step of processing ibuprofen, a hydrophilic polymer, and an inorganic excipient by an extrusion process to produce an extruded composition in which the ibuprofen forms a solid dispersion/solution within the hydrophilic polymer. The invention is particularly useful in preparing oral dissolvable tablets. Also provided are composition comprising an inorganic excipient and ibuprofen within a hydrophilic polymer.

Abstract: A method of producing an extruded, powdered/granulated composition comprising an active pharmaceutical ingredient (API), by the steps of providing an API and a porous inorganic excipient, and processing them by an extrusion process to directly produce an extruded, powdered/granulated composition wherein the API is at least partially absorbed within the pores of the inorganic excipient. In preferred embodiments, the API is melted, or solubilised in a solubilizer.

Abstract: A steel article is provided for improved wear resistance due to optimized hardness, toughness and temper resistance. In one exemplary embodiment, the steel article may have a composition including about 0,2 to 0.43 percent by weight of carbon, about 0.5 to about 3.0 percent by weight of silicon, about 0.01 to about 3.0 percent by weight of chromium, and 0.43 to about 2.5 percent by weight of vanadium.